相似文献
1
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
J Invest Dermatol. 2017 Apr;137(4):951-954. doi: 10.1016/j.jid.2016.10.044. Epub 2016 Nov 22.
2
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Dermatology. 2019;235(2):130-136. doi: 10.1159/000494613. Epub 2018 Dec 19.
3
Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
J Dermatolog Treat. 2017 Sep;28(6):476-483. doi: 10.1080/09546634.2016.1277179. Epub 2017 Jan 22.
4
Janus kinase inhibitors in dermatology: A systematic review.
J Am Acad Dermatol. 2017 Apr;76(4):745-753.e19. doi: 10.1016/j.jaad.2016.12.004. Epub 2017 Feb 4.
5
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Int J Dermatol. 2018 Dec;57(12):1464-1470. doi: 10.1111/ijd.14192. Epub 2018 Aug 30.
6
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Drugs Today (Barc). 2020 Feb;56(2):151-163. doi: 10.1358/dot.2020.56.2.3100503.
7
Safety of tofacitinib in IBD: A tricky puzzle.
United European Gastroenterol J. 2024 Jul;12(6):658-659. doi: 10.1002/ueg2.12587. Epub 2024 May 18.
8
JAK inhibitors in dermatology: The promise of a new drug class.
J Am Acad Dermatol. 2017 Apr;76(4):736-744. doi: 10.1016/j.jaad.2016.12.005. Epub 2017 Jan 28.
9
Journal club: JAK inhibitors and safety.
Eur J Dermatol. 2024 Jun 1;34(3):338-340. doi: 10.1684/ejd.2024.4716.
10
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
J Invest Dermatol. 2018 Jul;138(7):1539-1545. doi: 10.1016/j.jid.2018.01.032. Epub 2018 Feb 13.
引用本文的文献
1
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments.
Am J Clin Dermatol. 2024 Nov;25(6):927-950. doi: 10.1007/s40257-024-00886-9. Epub 2024 Sep 30.
2
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?
An Bras Dermatol. 2024 Jul-Aug;99(4):546-567. doi: 10.1016/j.abd.2023.10.002. Epub 2024 Mar 22.
3
Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms.
Cells. 2023 Oct 18;12(20):2473. doi: 10.3390/cells12202473.
4
HES and EGPA: Two Sides of the Same Coin.
Mayo Clin Proc. 2023 Jul;98(7):1054-1070. doi: 10.1016/j.mayocp.2023.02.013.
5
French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.
Orphanet J Rare Dis. 2023 Apr 30;18(1):100. doi: 10.1186/s13023-023-02696-4.
6
[Eosinophilic dermatoses].
Dermatologie (Heidelb). 2022 Dec;73(12):965-972. doi: 10.1007/s00105-022-05071-9. Epub 2022 Nov 15.
7
Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets.
Front Physiol. 2022 Jan 12;12:815842. doi: 10.3389/fphys.2021.815842. eCollection 2021.
8
Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?
Front Immunol. 2021 Oct 19;12:754413. doi: 10.3389/fimmu.2021.754413. eCollection 2021.
9
JAK inhibitors for asthma.
J Allergy Clin Immunol. 2021 Oct;148(4):953-963. doi: 10.1016/j.jaci.2021.08.013.
10
Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis.
BMJ Case Rep. 2021 Jul 15;14(7):e242240. doi: 10.1136/bcr-2021-242240.
本文引用的文献
1
Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome.
Blood. 2016 Feb 18;127(7):948-51. doi: 10.1182/blood-2015-06-654277. Epub 2015 Dec 23.
2
JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.
Br J Haematol. 2015 Oct;171(1):60-73. doi: 10.1111/bjh.13519. Epub 2015 Jun 15.
3
How I treat hypereosinophilic syndromes.
Blood. 2015 Aug 27;126(9):1069-77. doi: 10.1182/blood-2014-11-551614. Epub 2015 May 11.
4
World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Am J Hematol. 2014 Mar;89(3):325-37. doi: 10.1002/ajh.23664.
5
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.
J Allergy Clin Immunol. 2012 Sep;130(3):607-612.e9. doi: 10.1016/j.jaci.2012.02.019. Epub 2012 Mar 28.
6
The transcription factor STAT3 is required for T helper 2 cell development.
Immunity. 2011 Jan 28;34(1):39-49. doi: 10.1016/j.immuni.2010.12.013. Epub 2011 Jan 6.
7
Lymphocytic variant hypereosinophilic syndromes.
Immunol Allergy Clin North Am. 2007 Aug;27(3):389-413. doi: 10.1016/j.iac.2007.07.002.
8
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.
J Allergy Clin Immunol. 2006 Jun;117(6):1292-302. doi: 10.1016/j.jaci.2006.02.042. Epub 2006 May 3.
9
Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.
N Engl J Med. 1999 Oct 7;341(15):1112-20. doi: 10.1056/NEJM199910073411503.
Zotero 插件